Comparison of self‐expandable metallic stent placement followed by laparoscopic resection and elective laparoscopic surgery without stent placement for left‐sided colon cancer. by UEKI Tomoyuki et al.
Comparison of self‐expandable metallic stent
placement followed by laparoscopic resection
and elective laparoscopic surgery without
stent placement for left‐sided colon cancer.
著者 UEKI Tomoyuki, MIYAKE Toru, KOJIMA Masatsugu,








This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐
NoDerivs License, which permits use and distribution in any medium, provided the original work is
properly cited, the use is non‐commercial and no modifications or adaptations are made.
brought to you by COREView metadata, citation and similar papers at core.ac.uk
Ann Gastroenterol Surg. 2021;00:1–7.    |  1www.AGSjournal.com
 
Received: 1 October 2020  |  Revised: 14 November 2020  |  Accepted: 14 December 2020
DOI: 10.1002/ags3.12422  
O R I G I N A L  A R T I C L E
Comparison of self-expandable metallic stent placement 
followed by laparoscopic resection and elective laparoscopic 
surgery without stent placement for left-sided colon cancer
Tomoyuki Ueki  |   Toru Miyake |   Masatsugu Kojima |   Sachiko Kaida |   Hiroya Iida  | 
Tomoharu Shimizu  |   Masaji Tani
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of 
Gastroenterological Surgery
Department of Surgery, Shiga University of 
Medical Science, Shiga, Japan
Correspondence
Tomoyuki Ueki, Department of Surgery, 
Shiga University of Medical Science, 




Aim: Self-expandable metallic stent (SEMS) placement for obstructive colon cancer is 
widely performed as a bridge to surgery (BTS) procedure before resection. This study 
aimed to investigate the surgical and oncological results of laparoscopic elective sur-
gery with or without SEMS placement to assess the efficacy of SEMS placement as 
a BTS.
Methods: We retrospectively analyzed consecutive patients with stage II, III, and 
IV left-sided colon cancer who underwent elective laparoscopic resection between 
2013 and 2019. All patients were divided into two groups: with and without SEMS 
placement.
Results: The SEMS group included 24 patients, whereas the non-SEMS group in-
cluded 86 patients. The serum hemoglobin and albumin levels were lower (P = .049, 
P = .03), and the serum leukocyte and C-reactive protein levels were higher 
(P < .0001, P = .022) in the SEMS group. The tumor diameter and tumor circumferen-
tial rate were higher in the SEMS group (both P < .0001). No significant differences 
were observed in operation time, blood loss, postoperative complications, or post-
operative hospital stay. After 1:1 propensity score matching, 15 patients in the SEMS 
group were compared with 15 patients in the non-SEMS group. The 3-year overall 
survival rates of the SEMS and non-SEMS groups were 87.5% and 88.9%, respec-
tively (P = .97). The 3-year recurrence-free survival rates of the SEMS and non-SEMS 
groups were 58.2% and 81.7%, respectively (P = .233). No significant difference was 
found in the sites of recurrence.
Conclusion: The perioperative and long-term outcomes of SEMS placement as a BTS 
before laparoscopic resection could be acceptable compared with other elective lap-
aroscopic operations without SEMS placement.
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1  | INTRODUC TION
Acute colon obstruction caused by cancer has been reported to 
occur in up to 30% of patients and has been the main reason for 
emergency colonic surgery.1-3 Emergency surgery for acute ob-
struction due to colon cancer is associated with increased mor-
bidity and mortality compared with elective surgery.4,5 Placement 
of a self-expandable metallic stent (SEMS) was introduced for the 
palliative care of acute colon obstruction in the 1990s and thereaf-
ter started to be used as a bridge to surgery (BTS) procedure.6-9 In 
Japan, SEMS placement became available as a procedure covered 
by the national health insurance system in 2012. SEMS placement 
enables the avoidance of emergency surgery and the preparation 
of patients for curative resection with more detailed preopera-
tive examinations, including total colonoscopy.10 Furthermore, as 
SEMS placement provides a waiting time until surgery, patients 
can resume oral intake and undergo treatments for anemia and 
infection.11 Although several studies have reported acceptable 
short- and long-term outcomes of SEMS placement as a BTS,12-15 
another study was suspended because of a higher 30-day compli-
cation rate with BTS than with emergency surgery.16 Furthermore, 
the cohorts in some randomized controlled trials included many 
cases of perforation associated with SEMS placement and tech-
nical failure.17,18 On the basis of these conflicting results, the pre-
vious European guidelines stated that SEMS placement was not 
indicated as a curative-intent approach but might be performed 
for a palliative intent.19 However, in the latest guidelines, SEMS 
placement as a BTS is recommended by another meta-analysis 
that showed no differences in 5-year overall survival, 5-year dis-
ease-free survival, or local recurrence rate.20,21 Accordingly, the 
benefit of SEMS placement as a BTS remains controversial. The 
aim of this study was to verify the short-term effectiveness and 




We retrospectively analyzed 110 consecutive patients with stage 
II, III, and IV left-sided colon cancer with or without SEMS inser-
tion at Shiga University of Medical Science Hospital between 
2013 and 2019. In this study, patients whose tumor was located in 
the descending colon, sigmoid colon, and rectosigmoid colon were 
included, and those whose tumor was located in the splenic flex-
ure were excluded. A total of 24 patients underwent SEMS inser-
tion. The diagnosis of colon obstruction was made on the basis of 
the results of physical examination, contrast-enhanced computed 
tomography, and colonoscopy. To assess oral intake levels and ob-
structive symptoms before and after SEMS placement, we used 
the ColoRectal Obstruction Scoring System (CROSS) constructed 
by the Japan Colonic Stent Safe Procedure Research Group 
(JCSSPRG).22,23 The patients’ oral intake level was scored as fol-
lows: CROSS 0, requiring continuous decompression; CROSS 1, no 
oral intake; CROSS 2, liquid or enteral nutrient intake; CROSS 3, 
soft-solid, low-residue, and full diet with symptoms of stricture; or 
CROSS 4, soft-solid, low-residue, and full diet without symptoms 
of stricture. The decision of SEMS placement was made according 
to the patient's obstructive symptoms or after a discussion be-
tween the surgeon and the gastroenterologist. During the study 
period, a preoperative complication related to SEMS insertion 
(colon perforation by a guidewire) occurred in one patient, which 
needed emergency open surgery. The case was excluded from this 
study, because it was included in the exclusion criteria described 
below. All patients underwent elective laparoscopic resection. 
Patients with benign disease, distant metastasis, palliative care, 
and emergency surgery were excluded. Experienced gastroenter-
ologists performed endoscopic SEMS placement according to the 
JCSSPRG guidelines. Of the 110 patients, 61 (55.5%) were men 
and 49 (44.5%) were women. The mean age of the patients was 
71 years (range, 38-87 years) and the median follow-up period was 
30.5 months (range, 0.8-77.7 months). Postoperative complica-
tions were classified according to the Clavien-Dindo classification 
version 5.0.
2.2 | Statistical analysis
Quantitative variables are presented as median (range), and cat-
egorical variables are reported as absolute numbers and percent-
ages. Quantitative variables were analyzed using Student's t test. 
Categorical variables were compared using Pearson's chi-square 
test. Survival curves were plotted according to the Kaplan-
Meier method, and differences between survival distributions 
were assessed using the log-rank test. To reduce the effects of 
confounding factors in the two groups, propensity score match-
ing was performed for overall survival (OS) and recurrence-free 
survival (RFS). Propensity scores were derived using the following 
variables: age, sex, tumor location, tumor depth, tumor diameter, 
pathological stage, and adjuvant chemotherapy. Subsequently, 
patients in the SEMS group were matched to patients in the non-
SEMS group according to propensity scores. JMP software ver-
sion 10 (SAS Institute Inc, Cary, NC, USA) was used for statistical 
analyses, and differences with P-values <.05 were considered 
significant.
K E Y W O R D S
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3  | RESULTS
3.1 | Patient characteristics
The patients’ characteristics are summarized in Table 1. Of the pa-
tients, 24 underwent SEMS insertion and 86 did not. A WallFlexTM 
colonic stent (Boston Scientific Inc, USA) was inserted in three 
patients, and Niti-STM (TaeWoong Medical Inc, Korea) was in-
serted in 21 patients. Age, sex, and preoperative tumor marker 
levels were comparable between the two groups. In the blood 
biochemical tests at the first visit, the serum hemoglobin and al-
bumin levels were significantly lower (P = .049, P = .031), and the 
serum leukocyte and C-reactive protein (CRP) levels were signifi-
cantly higher (P < .0001, P = .023) in the SEMS group. However, 
after SEMS placement, no significant differences were found be-
tween the two groups in serum hemoglobin, albumin, leukocyte, 
or CRP levels (data not shown). The histopathological character-
istics are summarized in Table 1. The tumor was located in the 
descending colon in six patients (5.5%), in the sigmoid colon in 
59 patients (53.6%), and in the rectosigmoid colon in 45 patients 
(40.9%). Significant differences in tumor diameter and tumor cir-
cumferential rate were observed between the two groups (both 
P < .0001). The patients’ oral intake levels were scored as CROSS 
0 in eight patients (33.3%), CROSS 2 in four patients (16.7%), 
CROSS 3 in seven patients (29.2%), and CROSS 4 in five patients 
(20.8%). The median interval between SEMS placement and sur-
gery was 21 days.
3.2 | Surgical outcomes
With respect to surgical outcomes, no differences were observed 
between the two groups, except for the surgical procedure and di-
verting stoma construction rate (P = .018, P = .0001; Table 2). As 
shown in Table 2, postoperative complications (Clavien-Dindo clas-
sification version 5.0 grade II or higher) were observed in four cases 
(16.7%) in the SEMS group and in 17 cases (19.8%) in the non-SEMS 
group (P = .733). In the non-SEMS group, anastomotic leakage oc-
curred in two of 86 patients (2.3%). All patients recovered with con-
servative treatment. Postoperative mortality was not observed in 
either group. The median postoperative hospital stay was 11 days 
in the SEMS group and 10 days in the non-SEMS group (P = .74). In 
terms of adjuvant chemotherapy, the SEMS group had a relatively 
lower rate than the non-SEMS group, although the difference was 
not significant (P = .13).
3.3 | Long-term outcomes
Among the pathological stage II and III patients in the two groups 
(SEMS group, n = 18; non-SEMS group, n = 73), five in the SEMS 
group (27.8%) and 10 in the non-SEMS group (13.7%, P = .149) ex-
perienced recurrence. In the SEMS group, the most common sites of 
TA B L E  1   Patients’ characteristics
SEMS (n = 24)
Non-SEMS 
(n = 86) P value
Age (year)a  75 (51-86) 71 (38-87) .922
Gender (n (%))
Male 14 (58.3%) 47 (54.7%) .748
Female 10 (41.7%) 39 (45.3%)
Hemoglobin (g/dL) a  11.2 (6.7-14.4) 12.1 (7.1-17.1) .049
Leukocyte (×103/μL) a  7.2 (2.8-18.7) 5.65 (2.7-9.5) <.0001
CRP (mg/dL) a  0.36 (0.02-20.88) 0.18 (0-4.98) .023
Albumin (g/dL) a  3.45 (2.6-4.4) 3.7 (2.7-4.6) .031
CEA (ng/mL) a  10.75 (0.5-213) 5 (1-6922.1) .675
CA19-9 (U/ml) a  19 (1-102) 16 (1-576) .615
Tumor location (n (%))
Descending colon 2 (8.3%) 4 (4.7%) .189
Sigmoid colon 16 (66.7%) 43 (50%)
Rectosigmoid colon 6 (25%) 39 (45.3%)
Tumor depth (n (%))
T3 14 (58.3%) 62 (72.1%) .09
T4a 10 (41.7%) 19 (22.1%)
T4b 0 (0%) 5 (5.8%)
Tumor diameter (mm) a  60 (29-84) 40 (15-95) <.0001
Circumferential rate 
(%)a 
100 (60-100) 69.5 (19-100) <.0001
Harvested lymph 
nodes a 
20 (11-44) 20 (2-56) .653
Lymph node metastasis (n (%))
0 12 (50%) 40 (46.5%) .694
1 6 (25%) 30 (34.9%)
2 6 (25%) 15 (17.4%)
3 0 (0%) 1 (1.2%)
Histological differentiation (n (%))
Well 3 (12.5%) 22 (25.6%) .58
Moderate 19 (79.2%) 59 (68.6%)
Poor/ mucinous 2 (8.3%) 5 (5.8%)
Vascular invasion (n (%))
+ 19 (79.2%) 69 (80.2%) .91
− 5 (20.8%) 17 (19.8%)
Lymphatic invasion (n (%))
+ 15 (62.5%) 51 (59.3%) .777
− 9 (37.5%) 35 (40.7%)
Stage (n (%))
II 11 (45.8%) 40 (46.5%) .472
III 7 (29.2%) 33 (38.4%)
IV 6 (25%) 13 (15.1%)
Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, 
carcinoembryonic antigen; CRP, C-reactive protein; SEMS, self-
expandable metallic stent.
aData are presented as median (range). P-values <.05 were considered 
significant. 
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recurrence were the liver (n = 2) and lymph node (n = 2), followed 
by the lung (n = 1). In the non-SEMS group, the most common re-
currence patterns were recurrence in the liver (n = 4), followed by 
recurrence in the lung (n = 2), peritoneal seeding (n = 2), and local 
recurrence (n = 2). The sites of recurrence were not significantly dif-
ferent between the two groups (P = .199). To reduce the effects of 
confounding factors in the two groups, propensity score matching 
analysis was performed for OS and RFS. The following confound-
ers were included in propensity score matching: age, sex, tumor 
location, tumor depth, tumor diameter, pathological stage, and ad-
juvant chemotherapy. Propensity score matching was conducted to 
match 15 patients in the SEMS group and 15 patients in the non-
SEMS group in a 1:1 ratio. The characteristics of the matched co-
horts are shown in Tables 3 and 4. After matching, no significant 
differences were noted between the two groups. The 3-year OS rate 
after matching was 87.5% in the SEMS group and 88.9% in the non-
SEMS group (P = .97, Figure 1). The 3-year RFS rate after matching 
was 58.2% in the SEMS group and 81.7% in the non-SEMS group 
(P = .233, Figure 2).
4  | DISCUSSION
SEMS were originally used for the palliative care of patients with 
obstructive colon cancer in the 1990s.6,7 Thereafter, the use of 
SEMS gradually expanded to include decompression followed by 
curative resection as a BTS.8,9 In Japan, SEMS became available as a 
procedure covered by the national health insurance system in 2012. 
Tomita et al reported that SEMS placement as a BTS for obstructive 
TA B L E  3   Patients’ characteristics after propensity score 
matching
SEMS (n = 15)
Non-SEMS 
(n = 15) P value
Age (year)a  70 (51-86) 74 (38-86) .709
Gender (n (%))
Male 8 (53.3%) 9 (60%) .712
Female 7 (46.7%) 6 (40%)
Hemoglobin (g/dL) a  11.7 (9.1-13.9) 10.6 (7.1-14.4) .227
Leukocyte (×103/μL) a  5.3 (3.5-9.1) 6.0 (4.0-8.1) .242
CRP (mg/dL) a  0.24 (0.01-1.76) 0.34 (0.03-1.47) .599
Albumin (g/dL) a  3.4 (2.9-4.2) 3.5 (2.8-4.3) .641
CEA (ng/mL) a  13.5 (0.5-195.9) 5.7 (1.3-18.6) .157
CA19-9 (U/ml) a  22.5 (1-102) 19 (5-38) .142
Tumor location (n (%))
Descending colon 0 (0%) 2 (13.3%) .335
Sigmoid colon 11 (73.3%) 10 (66.7%)
Rectosigmoid colon 4 (26.7%) 3 (20%)
Tumor depth (n (%))
T3 11 (73.3%) 12 (80%) .666
T4a 4 (26.7%) 3 (20%)
Tumor diameter (mm) a  60 (29-70) 53 (40-70) .394
Circumferential rate 
(%)a 
100 (60-100) 100 (49-100) .104
Harvested lymph 
nodes a 
20 (12-44) 26 (10-41) .162
Lymph node metastasis (n (%))
0 8 (53.3%) 9 (60%) .904
1 3 (20%) 3 (20%)
2 4 (26.7%) 3 (20%)
Histological differentiation (n (%))
Well 1 (6.7%) 4 (26.7%) .334
Moderate 13 (86.6%) 10 (66.6%)
Poor/ mucinous 1 (6.7%) 1 (6.7%)
Vascular invasion (n (%))
+ 10 (66.7%) 12 (80%) .409
− 5 (33.3%) 3 (20%)
Lymphatic invasion (n (%))
+ 9 (60%) 11 (73.3%) .439
− 6 (40%) 4 (26.7%)
Stage (n (%))
II 8 (53.3%) 9 (60%) .713
III 7 (46.7%) 6 (40%)
Abbreviations: CA19-9, carbohydrate antigen 19-9; CEA, 
carcinoembryonic antigen; CRP, C-reactive protein; SEMS, self-
expandable metallic stent.
aData are presented as median (range). P-values <.05 were considered 
significant. 




(n = 86) P value
Surgical procedure (n (%))
Left hemi-colectomy 6 (25%) 5 (5.8%) .018
Sigmoid colectomy 11 (45.8%) 35 (40.7%)
High anterior resection 6 (25%) 44 (51.2%)
Hartmann's procedure 1 (4.2%) 2 (2.3%)
Diverting stoma constructed 
after resection (n (%))
5 (21.7%) 1 (1.2%) .0001





Blood loss (g) a  0 (0-489) 0 (0-556) .456
Postoperative complication, ≧CD grade II (n (%))
+ 4 (16.7%) 17 (19.8%) .733
− 20 (83.3%) 69 (80.2%)
Postoperative hospital stay 
(day) a 
11 (8-19) 10 (7-63) .74
Adjuvant chemotherapy (n (%))
+ 5 (27.8%) 35 (47.9%) .13
− 13 (72.2%) 38 (52.1%)
Abbreviations: CD, Clavien-Dindo classification; SEMS, self-expandable 
metallic stent.
aData are presented as median (range). P-values <.05 were considered 
significant. 
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colorectal cancer was safe and effective with low morbidity, low 
mortality, and a low stoma construction rate, in their analysis of two 
multicenter prospective feasibility studies.10 Other previous studies 
also reported that SEMS placement was associated with tolerable 
surgical outcomes compared with transanal decompression tube 
insertion and diverting ileostomy creation.24,25 Furthermore, the 
improvement of bowel obstruction by SEMS placement has been 
suggested to contribute to the conversion of emergency surgery 
cases to elective surgery cases.10 This advantage has enabled pa-
tients to undergo more detailed preoperative examinations and to 
resume oral intake before curative resection.11 Our study found no 
differences in operation time, blood loss, postoperative complica-
tions, or postoperative hospital stay between the SEMS and non-
SEMS groups. These perioperative outcomes were equivalent to 
those reported in several previous studies.10,24,25 However, in the 
blood biochemical tests at the first visit, the serum hemoglobin and 
albumin levels were significantly lower, and the serum leukocyte and 
CRP levels were significantly higher in the SEMS group than in the 
non-SEMS group. Although obstructive colon cancer can worsen 
the patients’ general condition, no significant differences were 
found between the two groups in serum hemoglobin, albumin, leu-
kocyte, or CRP levels after SEMS placement. The improved general 
F I G U R E  1   Overall survival of 30 
pathological stage II and III colon 
cancer patients with and without SEMS 
placement after propensity score 
matching. SEMS, self-expandable metallic 
stent
SEMS (n = 15) Non-SEMS (n = 15) P value
Surgical procedure (n (%))
Left hemi-colectomy 4 (26.7%) 2 (13.3%) .656
Sigmoid colectomy 7 (46.6%) 8 (53.3%)
High anterior resection 4 (26.7%) 5 (33.4%)
Diverting stoma constructed after 
resection (n (%))
2 (13.3%) 0 (0%) .143
Operation time (minute)a  233 (137-409) 233 (140-349) .538
Blood loss (g) a  0 (0-450) 0 (0-556) .789
Postoperative complication, ≧CD grade II (n (%))
+ 3 (20%) 5 (33.3%) .409
− 12 (80%) 10 (66.7%)
Postoperative hospital stay (day) a  10 (9-18) 9 (7-18) .157
Adjuvant chemotherapy (n (%))
+ 5 (33.3%) 4 (26.7%) .69
− 10 (66.7%) 11 (73.3%)
Abbreviations: CD, Clavien-Dindo classification; SEMS, self-expandable metallic stent.
aData are presented as median (range). P-values <.05 were considered significant. 
TA B L E  4   Surgical characteristics and 
outcomes after propensity score matching
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conditions after SEMS placement in the SEMS group may have led 
to perioperative outcomes comparable to those of the non-SEMS 
group. However, patients in the SEMS group more frequently under-
went diverting ileostomy creation in this study. A possibility exists 
that a diverting stoma was constructed in the SEMS group accord-
ing to the surgeon's decision to prevent serious conditions in case 
of anastomotic leakage. However, although acceptable short-term 
outcomes of SEMS as a BTS have been reported, the long-term on-
cological outcomes remain controversial. Several studies have been 
conducted on the detrimental effects of SEMS placement on long-
term outcomes.26-28 Takahashi et al reported that SEMS placement 
leads to increased circulating tumor DNA levels and the possibility 
of increased recurrence.29 However, several studies, including ran-
domized control studies, have reported acceptable long-term out-
comes of SEMS as a BTS.30,31 In the study by Sato et al, the 3-year 
OS and disease-free survival rates were comparable between 
the SEMS group and the transanal decompression tube group.22 
Moreover, recent meta-analyses have reported no difference in 
long-term outcomes and no differences in distant or local recur-
rence rates between BTS and emergency surgery.3,32 In this study, 
we performed propensity score matching analysis with respect to 
long-term outcomes. No significant difference in OS or RFS was ob-
served between the SEMS and non-SEMS groups. Therefore, SEMS 
placement followed by laparoscopic resection was considered to 
have acceptable results compared with other elective laparoscopic 
operations without SEMS placement. Furthermore, the recurrence 
pattern was not significantly different between the two groups, as in 
previous reports.22,32
Our study had several limitations. First, this study had a retro-
spective design and was performed at a single institution. Second, 
the sample size was small. Third, the indications of SEMS placement 
for obstructive colon cancer were unclear. In fact, several patients in 
the SEMS group had no obstructive symptoms. Moreover, the median 
follow-up period was relatively short, and the observation period 
differed between the two groups (median 26.8 and 32.7 months). 
We expect that prospective multicenter studies with larger sample 
sizes will verify our results in the future. In conclusion, despite the 
above-mentioned limitations, the perioperative and long-term out-
comes of SEMS placement as a BTS before laparoscopic resection 
may be acceptable in comparison with other elective laparoscopic 
operations without SEMS placement. SEMS placement seems to be 
useful as a preoperative decompression modality for left-sided ob-
structive colon cancer.
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